Drug Trial Radar · NCT02175225
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
Last checked: Nov 19, 2026Latest source record: May 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
294
Actual
Start
Oct 2014
Primary completion
Feb 10, 2018
Study completion May 30, 2018
Sponsor
- Lead sponsor
- Beth Israel Deaconess Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS); Massachusetts General Hospital; University of Massachusetts, Worcester; University of Pennsylvania; Johns Hopkins University; Duke University; University of North Carolina; University of Florida; Henry Ford Hospital; Ohio State University; St. Joseph's Hospital and Medical Center, Phoenix; University of California, San Francisco; Oregon Health and Science University; Yale New Haven Health System Center for Healthcare Solutions; University of Iowa; Hartford Hospital; The University of Texas Health Science Center, Houston; Rhode Island Hospital; Stanford University; University of Washington; University of Calgary; Hopital de l'Enfant-Jesus; University of Alberta; Rush University Medical Center; University Hospitals Cleveland Medical Center; Columbia University; Weill Medical College of Cornell University; NYU Langone Health; Mount Sinai Hospital, New York; Loyola University
- First posted
- Jun 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.
Conditions
- Intracerebral Hemorrhage
Interventions
Deferoxamine MesylateDrug
Placebo (for Deferoxamine Mesylate)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 DaysTime frame: 90 days
- Number of Subjects Experiencing Serious Adverse EventsTime frame: 90 days
- Number of Subjects With Serious Adverse Events Within 7 DaysTime frame: 7 days
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital / Barrow Neurological Institute
Phoenix, Arizona
Stanford University Medical Center
Palo Alto, California
San Francisco General Hospital
San Francisco, California
Yale New Haven Hospital
New Haven, Connecticut
University of Florida
Jacksonville, Florida
Loyola University Medical Center
Chicago, Illinois
RUSH University Medical Center
Chicago, Illinois
University of Iowa Medical Center
Iowa City, Iowa
Johns Hopkins Hospital
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Columbia University
New York, New York
Mount Sinai Hospital
New York, New York
NYU Langone Medical Center
New York, New York
Weill Medical College of Cornell University
New York, New York
University of North Carolina Medical Center
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
University Hospital Case Medical Center
Cleveland, Ohio
The Ohio State University Medical Center
Columbus, Ohio
Oregon Health & Science University Medical Center
Portland, Oregon
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
University of Texas Health Sciences Center
Houston, Texas
CHU de Québec - Hôpital de l'Enfant-Jésus
Québec, Canada
Foothills Hospital - University of Calgary
Calgary, Alberta, Canada
University of Alberta - Mackenzie Health Sciences Centre
Edmonton, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.